Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2020 07:30 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th

OCALA, Fla. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to participate...
October 06, 2020 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS Clinical Trial of Ampligen

OCALA, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) is pleased to announce that it has received Institutional Review Board (IRB) approval for the expansion of the...
February 13, 2020 11:18 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech подает три предварительные заявки на патент использования Ampligen® против схожего с вирусом SARS нового коронавируса Ухань 2019 года

Ampligen® достиг 100% выживаемости при клинически достижимых уровнях дозировки для человека при вирусе SARS в экспериментах на животных Ampligen - ключ к предлагаемой универсальной коронавирусной...
February 13, 2020 11:18 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech dépose trois demandes de brevets provisoires pour Ampligen® en vue d'une utilisation contre le nouveau coronavirus 2019 de Wuhan semblable au SARS

Ampligen® a obtenu un taux de survie de 100 % à des niveaux de dosage humains cliniquement atteignables pour le SARS dans le cadre d'expérimentations sur des animaux Ampligen est essentiel dans...
February 11, 2020 06:30 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen® for Use Against the SARS-like Wuhan 2019 Novel Coronavirus

Ampligen® obtained 100% survival rate at clinically achievable human dosage levels for SARS in animal experiments Ampligen key to proposed broad-spectrum ‘universal’ coronavirus vaccine OCALA, Fla.,...
August 23, 2019 06:50 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS

OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat...
August 15, 2019 06:45 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials

OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
August 08, 2019 06:50 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®

OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting...
August 02, 2019 06:45 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribution Agreement Disclosed in a Recent SEC Filing

OCALA, Fla., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB) recently demanded and received retractions and corrections in two cases of inaccurate reporting due to AI...
June 28, 2019 07:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma CFO Adam Pascale Announces Retirement

OCALA, Fla., June 28, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that Adam Pascale is retiring from the position of Chief Financial Officer after nearly...